Cyclodextrin-based polymers for therapeutic delivery
AssigneeCerulean Pharma Inc.
InventorsThomas C. Crawford, Oliver S. Fetzer, Lawrence Alan Reiter, Marc Wolfgang
Life of this patent
Estimating the term…
Abstract
Methods and compositions relating to CDP-taxane conjugates are described herein.
Claims53
A method of treating cancer in a subject, wherein the subject has cancer and has received an anticancer agent, the method comprising administering to the subject a CDP-taxane conjugate in an amount effective to treat the cancer, to thereby treat the cancer.
-3. (canceled)
-9. (canceled)
A method of identifying a subject for treatment with a CDP-taxane conjugate, the method comprising identifying a subject having cancer who has received an anticancer agent;
- and
- administering a CDP-taxane conjugate to a subject in an amount effective to treat the cancer, to thereby treat the cancer.
(canceled)
A method of treating a chemotherapeutic sensitive, a chemotherapeutic refractory, a chemotherapeutic resistant, and/or a relapsed cancer in a subject, the method comprising administering a CDP-taxane conjugate to a subject in an amount effective to treat a chemotherapeutic sensitive, a chemotherapeutic refractory, a chemotherapeutic resistant, and/or a relapsed cancer, to thereby treat the chemotherapeutic sensitive, the chemotherapeutic refractory, the chemotherapeutic resistant, and/or the relapsed cancer.
-14. (canceled)
-20. (canceled)
A method of treating cancer in a subject, the method comprising administering a CDP-taxane conjugate, wherein the CDP-taxane conjugate has the following formula:
- wherein each L is independently a linker or absent, each D is independently a taxane or —OH, each comonomer comprises polyethylene glycol (PEG), and n is at least 4, provided that the CDP-taxane conjugate comprises at least one taxane selected from docetaxel, larotaxel, and cabazitaxel, to a subject in an amount effective to treat the cancer, to thereby treat the cancer.
(canceled)
-25. (canceled)
A method of treating metastatic or locally advanced breast cancer in a subject, the method comprising providing a subject who has metastatic or locally advanced breast cancer and has been treated with a chemotherapeutic agent which did not effectively treat the cancer or which had an unacceptable side effect, and
- administering a CDP-taxane conjugate to a subject in an amount effective to treat the cancer, to thereby treat the cancer.
-36. (canceled)
A method of treating hormone refractory prostate cancer in a subject, the method comprising:
- providing a subject who has hormone refractory prostate cancer and has been treated with a chemotherapeutic agent that did not effectively treat the cancer or who had an unacceptable side effect, and
- administering a CDP-taxane conjugate to a subject in an amount effective to treat the cancer, to thereby treat the cancer.
-54. (canceled)
-131. (canceled)
A method of identifying a subject having cancer for treatment with a CDP-taxane conjugate, the method comprising
- identifying a subject having cancer who has received an anticancer agent and has a neutrophil count less than a standard;
- and
- identifying the subject as suitable for treatment with a CDP-taxane conjugate.
-137. (canceled)
A method of treating a subject having cancer, the method comprising selecting a subject having cancer who has received an anticancer agent and has a neutrophil count less than a standard;
- and
- administering a CDP-taxane conjugate to the subject in an amount effective to treat the cancer, to thereby treat the cancer.
-141. (canceled)
A method for selecting a subject having cancer for treatment with a CDP-taxane conjugate, the method comprising:
- determining whether a subject with a proliferative disorder has moderate to severe neutropenia;
- and
- selecting a subject for treatment with a CDP-taxane conjugate on the basis that the subject has moderate to severe neutropenia.
-146. (canceled)
A method for treating a subject having cancer, the method comprising:
- selecting a subject with cancer who has moderate to severe neutropenia;
- and
- administering a CDP-taxane conjugate to the subject in an amount effective to treat the cancer, to thereby treat the cancer.
-151. (canceled)
A method for selecting a subject having cancer for treatment with a CDP-taxane conjugate, the method comprising:
- determining whether a subject with cancer, has experienced neuropathy from treatment with an anticancer agent;
- and
- selecting a subject for treatment with a CDP-taxane conjugate, on the basis that the subject has experienced neuropathy from treatment with an anticancer agent.
-157. (canceled)
A method for treating a subject having cancer, the method comprising:
- selecting a subject with cancer who has experienced one or more symptom of neuropathy from treatment with a anticancer agent;
- and
- administering a CDP-taxane conjugate, to the subject in an amount effective to treat the cancer, to thereby treat the cancer.
-179. (canceled)
A method of selecting a subject having cancer, for treatment with a CDP-taxane conjugate, the method comprising:
- determining if a subject having cancer has or is at risk of having hepatic impairment, e.g., determining alanine aminotransferase (ALT), aspartate aminotransferase (AST) and/or bilirubin levels in a subject having cancer;
- and
- selecting a subject having hepatic impairment, e.g., a subject having ALT and/or AST levels greater than 1.5 times the upper limit of normal (ULN) and/or bilirubin levels greater than 2 times the ULN, for treatment with a CDP-taxane conjugate.
(canceled)
A method of treating a subject having cancer, the method comprising:
- selecting a subject with cancer who has or is at risk of having hepatic impairment, e.g., a subject having alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) levels greater than 1.5 times the upper limit of normal (ULN) and/or bilirubin levels greater than 2 times the ULN;
- and
- administering a CDP-taxane conjugate to the subject in an amount effective to treat the cancer, to thereby treat the cancer.
(canceled)
A method of selecting a subject having cancer, for treatment with a CDP-taxane conjugate, the method comprising:
- determining if a subject having cancer has or is at risk of having hepatic impairment, e.g., determining alkaline phosphatase (ALP), serum glutamate oxaloacetate transaminase (SGOT), serum glutamate pyruvate transaminase (SGPT) and/or bilirubin levels in the subject having cancer;
- and
- selecting a subject having or at risk of having hepatic impairment, e.g., a subject having ALP levels greater than 2.5 times the upper limit of normal (ULN), SGOT and/or SGPT levels greater than 1.5 times the upper limit of normal (ULN) and/or bilirubin levels greater than the ULN for treatment with a CDP-taxane conjugate.
(canceled)
A method of treating a subject having cancer, the method comprising:
- selecting a subject with cancer who has or is at risk of having hepatic impairment, e.g., a subject having alkaline phosphatase (ALP) levels greater than 2.5 times the upper limit of normal (ULN), serum glutamate oxaloacetate transaminase (SGOT) and/or serum glutamate pyruvate transaminase (SGPT) levels greater than 1.5 times the ULN and/or bilirubin levels greater than the ULN;
- and
- administering a CDP-taxane conjugate to the subject in an amount effective to treat the cancer, to thereby treat the cancer.
(canceled)
A method of selecting a subject having cancer, for treatment with a CDP-taxane conjugate, the method comprising:
- determining if a subject having cancer is currently being administered or will be administered a cytochrome P450 isoenzyme and/or a CYP2C8 inhibitor;
- and
- selecting a subject with cancer who is currently being administered or will be administered a cytochrome P450 isoenzyme and/or a CYP2C8 inhibitor, for treatment with a CDP-taxane conjugate.
-191. (canceled)
A method of treating a subject having cancer, the method comprising:
- selecting a subject having cancer who is currently being administered or will be, administered a cytochrome P450 isoenzyme, and/or a CYP2C8 inhibitor;
- and
- administering a CDP-taxane conjugate to the subject at a dose described herein, to thereby treat the cancer.
-197. (canceled)
A method of selecting a subject having cancer, for treatment with a CDP-taxane conjugate, the method comprising:
- determining if a subject with cancer is at risk for or has diarrhea or has experienced diarrhea from treatment with an anticancer agent, and
- selecting a subject who is at risk for or has diarrhea or has experienced diarrhea from treatment with an anticancer agent for treatment a CDP-taxane conjugate.
(canceled)
A CDP-taxane conjugate having the following formula:
- wherein each L is independently a linker or absent, each D is independently a taxane or —OH each comonomer comprises polyethylene glycol (PEG), and n is at least 4, provided that the CDP-taxane conjugate comprises at least one taxane selected from docetaxel, larotaxel, and cabazitaxel.
-204. (canceled)
(canceled)
Dependencies are inferred from the claim text.